Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-001747
Filing Date
2024-11-05
Accepted
2024-11-05 16:05:55
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20240930x10q.htm   iXBRL 10-Q 797358
2 EX-31.1 enzn-20240930xex31d1.htm EX-31.1 12843
3 EX-32.1 enzn-20240930xex32d1.htm EX-32.1 6413
  Complete submission text file 0001410578-24-001747.txt   3339262

Data Files

Seq Description Document Type Size
4 EX-101.SCH enzn-20240930.xsd EX-101.SCH 31463
5 EX-101.CAL enzn-20240930_cal.xml EX-101.CAL 19369
6 EX-101.DEF enzn-20240930_def.xml EX-101.DEF 100057
7 EX-101.LAB enzn-20240930_lab.xml EX-101.LAB 224021
8 EX-101.PRE enzn-20240930_pre.xml EX-101.PRE 173908
56 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20240930x10q_htm.xml XML 345679
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 241427445
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)